Can Ozempic Cause Weight Gain? Understanding the Complexities

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Weight gain is not a pharmacological effect of semaglutide, and it does not appear as an adverse reaction in the labeling. What does happen — reliably, and across the whole drug class — is weight regain after the medication stops. Randomised withdrawal trials including STEP 4 and SURMOUNT-4 show that discontinuation is consistently followed by rapid regain, and a 2026 review in EClinicalMedicine reports that roughly two-thirds of lost weight is typically regained within a year of stopping. That is a different phenomenon from a drug causing weight gain, and the distinction matters clinically.

What the Label Reports as Adverse Reactions

The Ozempic prescribing information lists the most common adverse reactions reported in at least 5% of treated patients as nausea, vomiting, diarrhoea, abdominal pain and constipation. Weight gain is not among them.

The mechanism runs the other direction. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying, potentiates glucose-dependent insulin secretion and participates in appetite regulation. Weight reduction was consistently observed across the trial programme, which is why Wegovy holds weight-management indications at all.

It is worth restating the product distinction, since the question is usually asked about the wrong brand: Ozempic is approved only for type 2 diabetes indications. Wegovy is the semaglutide product carrying the weight-management indications.

Why Regain After Stopping Is Physiological, Not Failure

Recent reviews frame this explicitly. A 2026 review in Cureus describes weight regain after GLP-1-based therapy discontinuation as disease recurrence rather than therapeutic failure, reinforcing obesity as a chronic, relapsing condition. After treatment stops, homeostatic weight-defence mechanisms re-emerge and favour a return toward the pre-treatment set point.

Cardiometabolic improvements tend to reverse alongside the weight. That pattern is what the randomised withdrawal designs were built to detect, and they detected it consistently.

The labeled indication reflects this. Wegovy’s weight indication is written as reducing excess body weight and maintaining weight reduction long term — maintenance is part of the approved use, not an optional extension of it.

Intermittent Use Produces the Appearance of Weight Gain

Real-world data cited in recent reviews indicate that a substantial share of GLP-1 receptor agonist users discontinue within a year of initiation. Coverage lapses, supply interruptions, cost and adverse effects all contribute.

A stop-start pattern produces a weight trace that rises during gaps, and from the inside that reads as the medication causing gain. What it actually reflects is the absence of exposure during those intervals, and semaglutide’s roughly one-week elimination half-life means exposure declines over weeks rather than instantly.

Fluid, Glycogen and the First Few Weeks

Early weight movement on any therapy that changes energy intake is dominated by fluid and glycogen shifts rather than by fat mass. Those shifts run in both directions and can produce a few pounds of apparent gain that has nothing to do with adipose tissue.

The clinical trials avoided this problem by measuring over 68 and 72 weeks. Week-to-week self-weighing is the least informative measurement available and the one most likely to generate a false alarm.

Situations Where Weight Genuinely Rises During Treatment

It happens, and there are ordinary explanations worth checking with a prescriber before drawing conclusions. Other medications can contribute to weight gain, and reviewing the full medication list is a standard first step. Untreated or newly emerging conditions can as well.

Reduced physical activity is another. Recent reviews of second-generation obesity medications raise lean mass loss as a live concern and emphasise that lifestyle intervention remains the foundation of care during pharmacotherapy, not an optional add-on.

And the plateau itself is frequently misread. When the weight curve flattens after the steep early phase, small upward fluctuations around a stable level are normal and are not the same thing as a trend reversal.

What to Do With the Observation

Bring a three-month trend rather than a set of daily readings, and bring the full medication list. Ask whether dosing has actually been continuous, since gaps are the most common explanation.

If discontinuation is on the table for any reason — cost, coverage, tolerability — plan it with your prescriber, because the withdrawal literature is unambiguous about what follows an unplanned stop. That planning conversation is the single most useful thing to have before it becomes urgent.

What the Withdrawal Trials Were Designed to Show

Randomised withdrawal designs exist precisely because uncontrolled observation cannot separate drug effect from natural history. Participants reach a maintenance dosage, are then randomised to continue or to switch to placebo, and the divergence between arms is attributable to the medication.

Wegovy Study 5 used exactly this structure: of 902 patients who entered a 20-week run-in that included 16 weeks of dose escalation, 803 reached the 2.4 mg maintenance dosage and were then randomised in a 2:1 ratio to continue or to receive placebo. Mean body weight at randomisation was 96.1 kg, down from 106.8 kg at baseline.

The finding that regain follows withdrawal is therefore not an artefact of people drifting back to old habits. It is a measured, randomised comparison, which is why current reviews describe it as disease recurrence rather than as behavioural failure.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Does Ozempic cause weight gain?

No. Weight gain does not appear as an adverse reaction in the labeling; the most common adverse reactions reported in at least 5% of treated patients are nausea, vomiting, diarrhoea, abdominal pain and constipation. Semaglutide slows gastric emptying and participates in appetite regulation, and weight reduction was consistently observed across the clinical programme.

Why do people regain weight after stopping?

Randomised withdrawal trials including STEP 4 and SURMOUNT-4 show that discontinuation is consistently followed by rapid weight regain and decline in cardiometabolic benefits. Reviews describe this as recurrence of a chronic relapsing condition: once pharmacological appetite suppression is removed, homeostatic weight-defence mechanisms re-emerge and favour a return toward the pre-treatment set point.

How much weight is typically regained?

A 2026 review in EClinicalMedicine reports that two-thirds of lost weight is typically regained within a year of discontinuation, often accompanied by reversal of cardiometabolic improvements. The same review notes that real-world data show up to 65% of GLP-1 receptor agonist users discontinue within a year of initiation, which makes this a common rather than rare trajectory.

Could my weight rise while I am still taking it?

It can, and there are ordinary explanations to check with a prescriber: other medications that contribute to weight gain, newly emerging conditions, reduced physical activity, or gaps in dosing. Early weight movement is also dominated by fluid and glycogen shifts, and a plateau with small fluctuations around a stable level is not the same as a trend reversal.

Should I stop if my weight goes up?

That is a conversation for your prescriber, not a unilateral decision. Bring a three-month trend rather than daily readings, along with a complete medication list, and establish first whether dosing has been continuous. Given the documented pattern of regain after discontinuation, any planned stop is better managed with clinical input than without it.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.